120M+ cells and 225,000 perturbation interactions will accelerate virtual cell model development in a first-of-its-kind partnership and will be released open source as part of a shared commitment to open science. SAN FRANCISCO & PALO ALTO, Calif. & REDWOOD CITY, Calif.–(BUSINESS WIRE)–Tahoe Therapeutics, Arc Institute, and Biohub announced a landmark initiative to generate the largest … [Read more…]

AUSTIN, Texas–(BUSINESS WIRE)–Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing and precision medicine, today announced a new collaboration with NVIDIA to accelerate the development of Natera’s multimodal AI foundation model platform and expand applications across precision medicine. Under the collaboration, Natera will integrate its unique longitudinal and multi-time point in vivo datasets and … [Read more…]

Phase 1/2a ELIMINATE-B trial for PBGENE-HBV ongoing across multiple dosing cohorts; Data updates expected at medical conferences in 2026 PBGENE-DMD expecting IND clearance in Q1 2026 for Phase 1/2 FUNCTION-DMD study with initial data from multiple patients expected in 2026 Unaudited cash, cash equivalents, and restricted cash of approximately $137 million as of December 31, … [Read more…]

HALIFAX, England–(BUSINESS WIRE)–Physical Properties Testers Group Limited (“PPT” or the “Company”), a global leader in physical property test and measurement solutions, announced today the appointment of Mark Fleiner as its new Chief Executive Officer, and Rebecca Henry as its new Chief Financial Officer, both effective January 5, 2026. PPT is a portfolio company of SK … [Read more…]

WOODBRIDGE, Conn.–(BUSINESS WIRE)–ChemWerth, Inc., a global leader in generic active pharmaceutical ingredient (API) development and supply, continues to expand its footprint and strengthen its position in the Indian market. To support its growth in the region, ChemWerth has hired Chandrakanth Reddy as general sales manager of its India office. “The addition of a general sales … [Read more…]

Reported preliminary, unaudited Data and application revenue of ~$316 million for the full year 2025, representing ~31% year-over-year growth, with Insights (data licensing) growing 38% 2025 Net revenue retention of ~126% CHICAGO–(BUSINESS WIRE)–Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a record Total Contract … [Read more…]

– Cabozantinib franchise achieves approximately $2.123 billion in preliminary U.S. net product revenues for fiscal year 2025 – – Fiscal year 2026 net product revenues guidance of $2.325 billion – $2.425 billion – – Presentation and webcast at J.P. Morgan 2026 Healthcare Conference tomorrow, Monday, January 12th at 5:15 p.m. PT / 8:15 p.m. ET … [Read more…]

Genialis Expressions empowers drug development teams to make confident decisions by unifying workflows and standardizing omics data for enterprise-grade clarity and comparability across studies BOSTON & LAUSANNE, Switzerland–(BUSINESS WIRE)–#ISO27001—Genialis, the RNA biomarker company, today announced that Swiss-based biopharmaceutical company Debiopharm has deployed the Genialis™ Expressions software platform within its cloud infrastructure to support biomarker discovery … [Read more…]

Financing round led by RA Capital Management and Forge Life Science Partners, with contributions from new and existing investors Proceeds to advance frevecitinib, an inhaled pan-JAK inhibitor with the potential to treat the broad severe asthma population, through Phase 2 studies BOSTON–(BUSINESS WIRE)–Kinaset Therapeutics, a clinical-stage biopharmaceutical company developing a novel and differentiated inhaled therapeutic … [Read more…]

Cohort 3 analysis from the BREAKWATER study shows objective response rate of 64% with BRAFTOVI plus cetuximab and FOLFIRI compared to 39% with standard-of-care treatment FOLFIRI with or without bevacizumab The BREAKWATER study demonstrates clinically meaningful and statistically significant results, which show potential flexibility in chemotherapy backbone for patients with BRAF V600E-mutant metastatic colorectal cancer … [Read more…]